Dengue virus envelope protein and pre-membrane protein (E protein (Envelope) and prM protein (pre-membrane))

The Dengue virus envelope protein (E) and pre-membrane protein (prM) are the principal surface structural proteins of the dengue virion. Envelope protein E mediates crucial processes in the viral lifecycle, including attachment to host cell receptors, membrane fusion with the endosome, and subsequent delivery of the viral genome into the cytosol. E protein is organized into three domains (DI, DII with the fusion loop, and DIII) and undergoes dramatic conformational changes in response to the acidic endosomal environment, facilitating viral fusion and entry[1][2][4][5][6][7]. Pre-membrane protein (prM) pairs with envelope protein E in immature virions, acting as a chaperone to protect E from premature fusion activation during virus maturation; cleavage of prM in the maturing virion is required for infectivity[1]. Both proteins are principal targets for neutralizing antibodies, making them critical for vaccine and therapeutic design. Small-molecule inhibitors and peptide-based antivirals have been developed targeting E protein’s fusion loops and glycan-binding sites. Safety concerns include antibody-dependent enhancement—a phenomenon where sub-neutralizing antibody responses can facilitate secondary infections. Their role is distinct from host cell receptors, enzymes, or transporters; they function as viral glycoproteins essential for dengue virus infectivity and pathogenesis[1][2][3][4][5][6][7].

Other names

Envelope glycoproteinE proteinDengue Epre-membrane proteinprM protein

Inhibition of viral entry via blockade of envelope-mediated fusion and allosteric inhibition of fusion-inducing conformational change.